Walleye Capital
TXG icon

Walleye Capital’s 10x Genomics TXG Stock Holding History

Walleye Capital’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$257K Buy
+6,700
New +$176K ﹤0.01% 3300
2026
Q1 		– Sell
-5,600
Closed -$91.3K – 5006
2025
Q4 		$91.3K Buy
+5,600
New +$84.6K ﹤0.01% 3906
2025
Q2 		– Sell
-500
Closed -$4.37K – 5056
2025
Q1 		$4.37K Sell
500
-2,800
-85% -$35.3K ﹤0.01% 4107
2024
Q4 		$47.4K Sell
3,300
-17,200
-84% -$271K ﹤0.01% 4372
2024
Q3 		$463K Sell
20,500
-7,200
-26% -$149K ﹤0.01% 3367
2024
Q2 		$539K Buy
27,700
+25,600
+1,219% +$670K ﹤0.01% 3443
2024
Q1 		$78.8K Sell
2,100
-19,400
-90% -$852K ﹤0.01% 4507
2023
Q4 		$1.2M Sell
21,500
-17,400
-45% -$757K ﹤0.01% 2204
2023
Q3 		$1.6M Buy
38,900
+20,500
+111% +$1.07M ﹤0.01% 1896
2023
Q2 		$1.03M Buy
18,400
+16,700
+982% +$904K ﹤0.01% 1831
2023
Q1 		$94.8K Buy
1,700
+300
+21% +$14K ﹤0.01% 2961
2022
Q4 		$51K Buy
+1,400
New +$45.8K ﹤0.01% 2516

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Walleye Capital's TXG Position: Q2 2026 in Review

Walleye Capital opened a new position in 10x Genomics (TXG) in Q2 2026: 100 shares worth $3.83K. The stake represents ﹤0.01% of the portfolio and ranks #4556 among its holdings. This is a return to the name: Walleye Capital previously reported a position in TXG as recently as Q4 2025.

Walleye Capital first reported a position in TXG in Q2 2020 and has held it in 14 quarters since. The position peaked at $4.19M in Q4 2024. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Walleye Capital held 100 shares of 10x Genomics worth $3.83K as of Q2 2026.
  • 10x Genomics was a new Walleye Capital position in Q2 2026.
  • 10x Genomics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #4556 holding.
  • Walleye Capital first reported a position in 10x Genomics in Q2 2020 and has held it in 14 quarters since.
  • Walleye Capital's 10x Genomics position peaked at $4.19M in Q4 2024.
  • 392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.